当前位置：
X-MOL 学术
›
Lancet Respir. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2024-10-01 , DOI: 10.1016/s2213-2600(24)00186-3 Ruth L Goodall PhD, Prof Andrew J Nunn MSc, Prof Sarah K Meredith MBBS, Adamu Bayissa MD, Anuj K Bhatnagar MD, Prof Chen-Yuan Chiang PhD, Francesca Conradie MBBCh, Narendran Gopalan DNB, Meera Gurumurthy PhD, Bruce Kirenga PhD, Prof Nana Kiria PhD, Daniel Meressa MD, Ronelle Moodliar MMed, Nosipho Ngubane MBChB, Mohammed Rassool MBChB, Karen Sanders MSc, Rajesh Solanki MD, Prof S Bertel Squire PhD, Mekonnen Teferi MSc, Gabriela Torrea PhD, Bazarragchaa Tsogt PhD, Elena Tudor PhD, Armand Van Deun PhD, I D Rusen MD, STREAM study collaborators, Susan Adakun, Sofia Alexandru, Vignes Anand Srinivasulu, Bizuneh Belachew Mekuria, Katharine Bellenger, Deborah Bennet, Adugna Bezabih, Priyanka Bindroo, Ghanshyam Borisagar, Claire Cook, Andrew Davis, Bouke de Jong, Wendy Dodds, Anna Donica, Baasansuren Erkhembayar, Stella Fabiane, Tolera Gerbaba Bulga, Anne Goldfeld, Gareth Hughes, Ivan Kimuli, Jan Komrska, Daniel Legese Achalu, Nino Lomtadzec., Jason Madan, Nokuphiwa Mbhele, Brendan Murphy, Paranji Murugesan Ramesh, Thando Mwelase, Joanitah Nalunjogi, Naranbat Nyamdavaa, Leena Patel, Ishmael Qawiy, Mary Rauchenberger, Leen Rigouts, Laura Rosu, Ezio Santos-Filho, Rathinam Sridhar, Lisa White, Johanna Whitney, Eve Worrall
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2024-10-01 , DOI: 10.1016/s2213-2600(24)00186-3 Ruth L Goodall PhD, Prof Andrew J Nunn MSc, Prof Sarah K Meredith MBBS, Adamu Bayissa MD, Anuj K Bhatnagar MD, Prof Chen-Yuan Chiang PhD, Francesca Conradie MBBCh, Narendran Gopalan DNB, Meera Gurumurthy PhD, Bruce Kirenga PhD, Prof Nana Kiria PhD, Daniel Meressa MD, Ronelle Moodliar MMed, Nosipho Ngubane MBChB, Mohammed Rassool MBChB, Karen Sanders MSc, Rajesh Solanki MD, Prof S Bertel Squire PhD, Mekonnen Teferi MSc, Gabriela Torrea PhD, Bazarragchaa Tsogt PhD, Elena Tudor PhD, Armand Van Deun PhD, I D Rusen MD, STREAM study collaborators, Susan Adakun, Sofia Alexandru, Vignes Anand Srinivasulu, Bizuneh Belachew Mekuria, Katharine Bellenger, Deborah Bennet, Adugna Bezabih, Priyanka Bindroo, Ghanshyam Borisagar, Claire Cook, Andrew Davis, Bouke de Jong, Wendy Dodds, Anna Donica, Baasansuren Erkhembayar, Stella Fabiane, Tolera Gerbaba Bulga, Anne Goldfeld, Gareth Hughes, Ivan Kimuli, Jan Komrska, Daniel Legese Achalu, Nino Lomtadzec., Jason Madan, Nokuphiwa Mbhele, Brendan Murphy, Paranji Murugesan Ramesh, Thando Mwelase, Joanitah Nalunjogi, Naranbat Nyamdavaa, Leena Patel, Ishmael Qawiy, Mary Rauchenberger, Leen Rigouts, Laura Rosu, Ezio Santos-Filho, Rathinam Sridhar, Lisa White, Johanna Whitney, Eve Worrall
STREAM stage 2 showed that two bedaquiline-containing regimens (a 9-month all-oral regimen and a 6-month regimen with 8 weeks of aminoglycoside) had superior efficacy to a 9-month injectable-containing regimen for rifampicin-resistant tuberculosis up to 76 weeks after randomisation. Our objective in this follow-up analysis was to assess the durability of efficacy and safety, including mortality, at 132 weeks.
中文翻译：
两种治疗利福平耐药结核病（STREAM 2 期）的短期标准化方案的长期疗效和安全性：一项开放标签、多中心、随机、非劣效性试验的扩展随访
STREAM 第 2 阶段显示，两种含贝达喹啉的方案（一种 9 个月的全口服方案和一种 6 个月含氨基糖苷类药物的方案）对随机分组后长达 76 周的利福平耐药结核病的疗效优于含注射剂 9 个月的方案。我们在这项随访分析中的目的是评估 132 周时疗效和安全性的持久性，包括死亡率。
更新日期：2024-10-01
中文翻译：
两种治疗利福平耐药结核病（STREAM 2 期）的短期标准化方案的长期疗效和安全性：一项开放标签、多中心、随机、非劣效性试验的扩展随访
STREAM 第 2 阶段显示，两种含贝达喹啉的方案（一种 9 个月的全口服方案和一种 6 个月含氨基糖苷类药物的方案）对随机分组后长达 76 周的利福平耐药结核病的疗效优于含注射剂 9 个月的方案。我们在这项随访分析中的目的是评估 132 周时疗效和安全性的持久性，包括死亡率。
京公网安备 11010802027423号